Australia's largest stock trading and investment forum Australia's #1 stock forum

RRP

0.00%

8.5¢ realm resources limited

Revolt - Shares Holders, page-16

First 16 Last

Share
Profile

Follow
Paxti

331 Posts.

20

18/03/17

19:16

Post #: 23455824
Share

Originally posted by cammokazee ↑

Just scratching the surface but interesting when you start to dig a little in the top holders.

Andrew Martin Matheson previous managing director of realm resources.
M Resources managing director founder Matt Latimore - most likely has the other major holding in Latimore Family P/L.
Nine One Four P/L (previously Bain Family Super P/L) - perhaps Christopher Bain non-exec director of KGL (mining)?
Theo Renard - CFO secretary realm resources.

I would suggest other than the obvious ones that some of these top holdings and others listed are 'connected' private holdings or 'industry associates' (i use these terms loosely by the way). I would also suggest that several of these parties would therefore know more of what is really happening than you & i. Well there doesn't seem to be any great rumblings from anyone up above!

My point is that getting some of these shareholders on board with us 'may' not be that easy.

Anyway l hope this helpful. Please forgive me if any errors. DYOR etc etc

Also Berpaid P/L & Removale P/L are both held by David Benardi.

Expand

I think reaching 5% of the available shares is unlikely.

We should aim to call an EGM by securing 100 signatures from shareholders.

This will have the dual benefit or bringing directors to account and, I would anticipate, drawing considerable media attention.

Paxti.

RRP Price at posting: 4.1¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

AI stocks: What to expect in 2024-25

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability